Posted by Michael Wonder on 15 Sep 2020
Plus Therapeutics receives fast track designation from FDA for its novel glioblastoma treatment
15 September 2020 - Plus Therapeutics today announced that the U.S. FDA has granted the Company fast track designation for its lead investigational drug, Rhenium NanoLiposomes for the treatment of patients with recurrent glioblastoma.
As previously reported, the Company also received orphan drug designation from the FDA for Rhenium NanoLiposomes for the treatment of patients with glioblastoma.
